MBX Biosciences (MBX) Equity Ratio (2023 - 2026)

MBX Biosciences has disclosed Equity Ratio across 4 years of filings, most recently posting 0.97 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.97, up 1.01% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.97 (up 1.01% YoY), and the FY2025 annual result was 0.96, changed 0.0% from the prior year.
• Equity Ratio came in at 0.97 for Q1 2026 at MBX Biosciences, up from 0.96 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.97 in Q3 2025 to a low of 0.86 in Q4 2023.
• The 4-year median for Equity Ratio is 0.96 (2025), against an average of 0.73.
• Across the five-year window, Equity Ratio soared 211.36% in 2024 and slipped 0.0% in 2025, its largest moves.
• MBX Biosciences' Equity Ratio stood at 0.86 in 2023, then jumped by 211.36% to 0.96 in 2024, then slipped by 0.0% to 0.96 in 2025, then climbed by 0.87% to 0.97 in 2026.
• The last three Equity Ratio figures came in at 0.97 (Q1 2026), 0.96 (Q4 2025), and 0.97 (Q3 2025), per Business Quant data.